Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and the safety of KHK7580 orally
administered once daily for 52 weeks compared to cinacalcet hydrochloride as an active
control in subjects with secondary hyperparathyroidism receiving hemodialysis in China,
Korea, Hong Kong and Taiwan.
Phase:
Phase 3
Details
Lead Sponsor:
Kyowa Hakko Kirin Co., Ltd Kyowa Kirin Co., Ltd.
Collaborators:
Kyowa Hakko Kirin China Pharmaceutical Co., LTD. Kyowa Hakko Kirin Korea Co., Ltd. Kyowa Kirin Korea Co., Ltd.